Scott uses his ability to read situations, emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements, in both short and longer terms situations.. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. Sold Somatogen to Baxter International (BAX): Dr. Hoffman was the scientific founder of Somatogen Inc. Baxter bought out Somatogen for $189M. That's right -- they think these 10 stocks are even better buys. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. 6. Invest better with The Motley Fool. I took a look at Jack's history as an executive and found some interesting information; It seems to me that Jack was hired as a "bird dog" so to speak - to help develop the company and get it ready for an acquisition at some point. Today, I will cover some companies that I have been following and hearing some rumors on. Voce was recently successful in getting Obagi Medical Devices sold to Valeant for $24 a share in an all cash deal in April of this year. Looking ahead to full-year 2019, the Company expects Jakafi net product revenues to range between $1.65 billion and $1.68 billion, reflecting 20% to 22% growth over the prior year. The FDA has accepted the new drug application for adagrasib in NSCLC, with a PDUFA goal date of Dec. 14, 2022. Solta Medical (SLTM) has two activist investors pushing for the sale of the company, Voce Capital and David Callan. Some have merit and turn out to be true, while others turn out to be false and without merit. Antares Pharma ( ATRS ) We first began to hear acquisition rumors in Antares in late 2011. On the one hand, CAPLYTAs sales are growing significantly, on the other hand, the company has several product candidates with the potential to generate billions of dollars in sales in a few years. If the letter of intent to acquire your company has been signed, you might be asking what happens next. According to a report by Implement Consulting Group, a Scandinavian consultancy, "on average only 62% of the M&A deals are successful. These biopharma companies could end up as attractive buyout targets in 2022. But Brian, is there a biotech buyout that you would really like to see? 12. Any you had ideas about? With focus on discovery, development and commercialization of a strong product portfolio, collaborating with industry-leading partners such as Novartis and Sanofi Genzyme, and an outstanding therapeutics pipeline, Alnylam is one of those biotech gems big pharma companies have on their radar. Hunzinger said: Biotech and smaller medical device deals should continue in the first half of the year, with the second half poised for larger deals driven by a need for scale and an expected settling of the regulatory landscape.. The quest behind the drive is to fill potential gaps in the pipeline. 4. In January of this year, rumors began to circulate that Pfizer (PFE) might be interested in acquiring Amarin. ALXN is down 22% from its all-time high of $141.86, recorded on April 10, 2019, and trades around $110. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Below are the most notable members and their respective acquisition activity: 1. They are my opinions only. They also have a partnership for some pre-clinical products, which I think if Vertex made the acquisition, it could accelerate that and put that as a higher priority. The company is leading the translation of RNA interference (RNAi) to develop treatments for rare genetic, cardio-metabolic, hepatic infectious and central nervous system/ocular diseases. It remains to be seen if the takeover rumors are just wishful thinking or will turn into reality. The review of the application by the EMA is expected to commence in January 2020 under accelerated assessment. The Motley Fool has a disclosure policy. The rumors on Obagi turned out to be correct, as the company was sold last year to Valeant (VRX) for $24 a share. The post-operative pain market in the United States, Europe, and Japan has been growing steadily over the last few years and is expected to reach $6.5 billion by 2018. Like the Medicines Co., Amarin also has a heart drug by the name Vascepa in its kitty. Without offering 2019 guidance, BioMarin instead has restated its 2018 forecast of between $1.47 billion and $1.53 billiona jump of between 12% and 16.5% over 2017as well as a net loss of . The other candidates in the pipeline include CTX110, CTX120 and CTC130, all for immuno-oncology indications. Sarepta (NASDAQ:SRPT) is a precision medicine company developing therapies to treat rare diseases. Other approved drugs in the companys portfolio continue to do well. That's right -- they think these 10 stocks are even better buys. Antares Pharma. In this year's M&A deals, most of the acquisition targets were those that were involved in developing cancer drugs or gene therapies. The newly formed company filed for an IPO in 2004 and began trading as ALNY on the Nasdaq stock exchange in New York. Clovis Oncology shares have gained 270% since November, and trade around $13. The company's portfolio consists of a few commercialized products and multiple clinical and pre-clinical product candidates. *Average returns of all recommendations since inception. Learn More. Many of today's most influential medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Humira, might not have become so without mergers and acquisitions. BioNTech SE (Nasdaq: BNTX, "BioNTech") and InstaDeep Ltd. ("InstaDeep") today announced that they have entered into an agreement under which BioNTech will acquire InstaDeep, a leading global technology company in the field of artificial intelligence ("AI") and machine learning ("ML"). BioPharma Dive is tracking these deals below. Let's take a look at some of the biotech companies that have been in the acquisition crosshairs for quite some time. Incyte has an attractive pharmaceutical portfolio comprising of Jakafi, a blockbuster drug for rare blood cancer indications, and 3 other marketed drugs, and a well-stocked pipeline. Later, Bristol-Myers Squibb for $2.4B. The top ten deals in the industry totaled $97 billion in 2020, led by the $39-billion buyout of Alexion Pharmaceuticals ( ALXN) - Get Free Report late in the year by AstraZeneca ( AZN) - Get Free. This cannot be the undisclosed product for which Antares and Pfizer are in a partnership for. Since then, Alnylam has received FDA approval for several drugs and has developed a robust development pipeline. But TIGIT's an immune checkpoint inhibitor, so I think that would pair potentially quite nicely with Bristol-Myers Squibb's Opdivo. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Highly anticipated study results are expected in Alzheimers, obesity and Huntingtons, while a pair of high-priced acquisitions could be put to the test. Many members of the management came from ALZA Corporation, which was one of the most successful mergers in the above list. I wrote this article myself, and it expresses my own opinions. Written by Scott Matusow. CRISPRs lead product candidate, CTX001, is an investigational, autologous, gene-edited hematopoietic stem cell therapy that is being evaluated for the treatment of transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). *Average returns of all recommendations since inception. BioSpace is covering all the key announcements all week. RTTNews.com for Price as of January 17, 2023, 4:00 p.m. Antares Pharma (ATRS). Avulux is pleased to announce that Axon Optics is now part of the Avulux family. This submission marks the first marketing application submission for a gene therapy product for any type of hemophilia. Whether M&A activity continues will have a significant effect on which startups and drug programs get funded and advanced. Sold Kos Pharmaceuticals to Abbott Laboratories (ABT): Mr. Adams served as the President and Chief Executive Officer of Kos Pharmaceuticals, Inc. Abbott Laboratories bought out Kos Pharmaceuticals for $78 a share, or a 56% premium over the current share price. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. Gene-editing company Crispr (NASDAQ:CRSP) has long been considered as a potential M&A target owing to its promising technology platform and its longstanding partnership with Vertex Pharma (NASDAQ:VRTX). Immuno-oncology biotech Iovance Biotherapeutics' shares rocketed up by nearly 40% Tuesday on buyout chatter. Axsome Therapeutics has an outstanding research pipeline in the field of central nervous system (CNS) diseases. In the wake of generic drugs eating into the sales of off-patent branded drugs, growing pressure from regulators to reduce the prices of drugs, drying pipelines, and ever-increasing R&D costs, there has been an increasing consolidation within the drug industry. David Callan was actively involved SRI Surgical (Formerly Nasdaq listed STRC) unsolicited offer bid and eventual sale of the company. Now, it is three years since the PARP inhibitor has been approved. Merger and acquisition activity has been rather slow in the biopharma industry so far this year. His work with diagnostics development give him a strong background in immunology which is leveraged in evaluating immunology focused approaches. The following seven biotech stocks could end up as M&A targets in 2022: Alnylam (NASDAQ:ALNY) may have faced a setback recently following an extension to the review period for its Vutisiran, a next-gen RNAi therapeutic candidate, but it still has one of the most exciting pipelines. Alexion Pharma is no stranger to takeover rumors. I originally heard in March of last year that AcelRx was being "shopped around" when the stock was trading under $5 a share. Seagen has quite a few oncology drugs that would work well with the Bristol-Myers drugs. These symbols will be available throughout the site during your session. Editor's note: If tables or values do not display, please try clearing your browser's cache and reloading the page. Who will buy? Here's a look at the 10 top takeover targets. Keith Speights: All right, Brian. Sanofi has been quite active on the M&A front this year. Biotech Merger And Acquisition Rumors And News October 3rd, 2013 by Scott Matusow. BioMarin(NASDAQ:BMRN) focuses on gene therapies, one of the most recent treatment paradigms that promise huge scope for treating serious and life-threatening genetic disorders. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. Best Penny Stocks . Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. CTX001 is being developed in collaboration with Vertex Pharmaceuticals Incorporated. ATRS. At the time, I was . We first began to hear acquisition rumors in Antares in late 2011. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Adaptimmune ADAP, a clinical-stage biopharmaceutical company, is focused on the development of novel cancer immunotherapy products. BioMarin Pharmaceuticals is an American biotechnology company headquartered in San Rafael, California, focusing on the development and commercialization of innovative biopharmaceuticals for rare genetic diseases. Speights: Yeah. We first began to hear acquisition rumors in Antares in late 2011. There's a company called Adicet Bio (ACET 0.46%), ticker there is ACET, I believe. GLOBAL MARKETS-Stocks buoyed by cheery data after BOJ damp squib, Nouriel Roubini: There's a massive disconnect between markets and the Fed, U.S. natgas price slump pushes 'widow maker' toward unusual contango, Germany must speed hydrogen plans this year - gas pipeline group OGE, Ian Bremmer: We're in a hot war with Russia. Ionis (NASDAQ:IONS) is commercial-stage biopharma developing RNA-targeted therapy using antisense technology that can control gene expression in a cell using antisense oligonucleotides (ASO). The Motley Fool owns and recommends Axsome Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Seagen Inc., and Vertex Pharmaceuticals. Go and get the Biotech Investments HOT STOCK REPORT. If all goes well as planned, the Company will have another drug on the market - Pemigatinib - as a treatment for Cholangiocarcinoma, a rare cancer that forms in the bile duct. Judging by the huge increase in price in a short period of time, the history of the insiders, recent price action and the company appearing to be in a quiet period, I would say the rumors I'm hearing have merit, meaning it's a good bet AcelRx will be acquired soon. Source: Mongkolchon Akesin / Shutterstock.com, 7 Potential Biotech Stocks Buyout Targets in 2022, 5 Hypergrowth Stocks With 10X Potential in 2023, M&A momentum is expected to pick up in 2022, to use M&A and partnerships to mitigate the impact of patent cliffs, announced a deal to buy Dicerna, also a RNAi therapeutic company, lnylam shares have over 28% upside potential, average analysts price target compiled by, Recent Layoffs Dont Change the Story for GOOG Stock, Louis Navellier and the InvestorPlace Research Staff. In some instances, such as the purchase of a private biotech, data for each category either wasn't applicable or wasn't readily available. Want the latest recommendations from Zacks Investment Research? Therefore, leading companies such as CRISPR Therapeutics, Intellia Therapeutics, or Editas Medicine might catch the eye of large pharmaceutical companies trying to step into this field and complement their pipeline with CRISPR/Cas9 technology. In early 2017, the rumor mill was spinning with whispers of Gilead (GILD) close to acquiring Incyte. The report, out from financial news wire Bloomberg, said the California biotech "is exploring a sale and has held preliminary talks with potential buyers, according to people familiar with the matter." The company has already seven products on the market. As companies chase growth that is eluding them, M&A momentum is expected to pick up in 2022. Keith Speights owns shares of Vertex Pharmaceuticals. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. Alnylam stock has a market capitalization of over $20 billion. I own Vertex so I certainly don't want Vertex overpaying for CRISPR Therapeutics. Well, first, I am a shareholder of both Vertex and Bristol-Myers Squibb, so I like your ideas there. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. These deals haven't come cheap, however. But there are some deals that Motley Fool contributors Brian Orelli and Keith Speights hope will happen. 2019 saw more than 25 acquisition deals executed in the biotech sector, of which 14 were billion-dollar deals. 9. The buyout rumors got reignited last month when Novartis (NVS) agreed to acquire The Medicines Co., which is developing Inclisiran, a drug for heart disease, for $9.7 billion. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. Ra Medical Systems (NYSE American: RMED) announces a realignment of its board of directors in conjunction with the recently announced merger with Catheter Precision, Inc. David Jenkins has joined the board as Executive Chairman and James Caruso has been named director. Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. Two exceptions: Amgen's $13.4 billion acquisition of the psoriasis medicine Otezla and Novartis' $3.4 billion acquisition of the dry eye drug Xiidra, which are included for their notable size and importance to the acquirer. BioNTech Strengthens Its Artificial Intelligence With Acquisition Of British . Create your Watchlist to save your favorite quotes on Nasdaq.com. *Stock Advisor returns as of September 17, 2021. The FDA recently granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. Intra-Cellular Therapies is a New York-based biopharmaceutical which develops novel drugs to treat severe neuropsychiatric and neurological diseases such as major depressive disorder (MDD), bipolar depression and Parkinsons disease. Moreover, companies investing in mRNA technology are gaining a lot of attention, given the success of the technology in the development of COVID-19 vaccines. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year. All rights reserved. Scott has had the most success in trading/investing in smaller cap growth companies. Keep track of M&A as it happens with this database. Powered by Madgex Job Board Software. RTTNews->. Using these acquired allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis. These ASOs regulate the expression of a specific factor, which if present causes a particular disease. We at Biotech Investments see several catalysts that could make Intra-Cellular Therapies an interesting acquisition target. I also agree with you that Vertex, if there's going to be one of those massive big pharma mergers like we've seen over the last 20 years, some of those massive deals, I think Vertex would be an excellent candidate to be acquired by a bigger company. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. But that deadline has long passed. Shockwave Medical bolsters medical device portfolio with acquisition of Neovasc. Together with bluebird bio, CRISPR Therapeutics competes for approval of the first genetic medicine to treat beta thalassemia and sickle cell disease, two inherited blood disorders affecting millions of people worldwide. Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction. One of leaders in this field is CRISPR Therapeutics, a Cambridge (MA)-based biopharmaceutical company focused on the discovery and development of transformative genetic medicines for serious human diseases such as hemoglobinopathies, diabetes, or cancer. Additionally, Dan is a Scientist and inventor. 5 min read Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. The Motley Fool recommends Biogen and Gilead Sciences. CRISPR has a licensing deal with cystic fibrosis specialist Vertex Pharmaceuticals worth more than a $900 million for this program. Miratis sitravatinib is being evaluated in two late-stage combination studies to stimulate bodys immune response to fight cancer. The pipeline progress has been encouraging. Just recently, Bayer bought out Conceptus for $1.1B. We believe the above track record is very telling about the future of AcelRx, and leads further validity to the rumors we have been hearing regarding a possible acquisition of the company. Dealmaking is essential to the business of drug development. Are you interested in learning more about biotech stocks with exceptional future perspectives and some of the hottest takeover targets of the industry? Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. I think those could be intriguing deals for the new year. Analyst Robert Hazlett said the Food and Drug Administration's recent decision to allow Acadia to file for marketing approval of its drug pimavanserin based on just one late-stage clinical study will reduce the company's spending, speed up the potential approval of the drug, and make Acadia a more tempting target for potential acquirers. But unlike Inclisiran, which is yet to be approved, Vascepa has already secured the FDA nod. product. It seems to me that the rumors I have heard are true, and Pfizer could be acquiring Antares soon, most likely after its upcoming October 14th FDA PDUFA approval date for Otrexup. 4 Biotechs That Could Be Potential Acquisition Targets in 2021. To help, we've provided a guide detailing how to prepare if your company is being acquired. AcelRx (ACRX). Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. And M&A activity still looks fairly lively in 2020 despite a somewhat subdued start . The speculation gained further ground when Denmark-based Novo Nordisk (NYSE:NVO) announced a deal to buy Dicerna, also a RNAi therapeutic company. 1985 - 2023 BioSpace.com. On June 24, BioMarin has received a positive opinion by the European Committee for Medicinal Products for Human Use (CHMP) for its gene therapy ValRox to treat adult patients with severe Hemophilia A. The average deal size also shrank from the historical mean of $4.3 billion to $2.8 billion. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. The downside is that I'm not really sure Vertex wants to get into the CAR-T business, which is basically the other half of CRISPR's clinical pipeline. Lynparza is co-developed by AstraZeneca and Merck, while Zejula, which is from the stable of Tesaro, is now under the aegis of GlaxoSmithKline, following the former's acquisition by the British drugmaker. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Scott has long positions in 3 companies mentioned in this article. AMRN closed Friday's trading at $24.12, up 4.92%. Keith Speights: Let's switch gears. The Company submitted a Marketing Authorization Application to the. The best transactions benefit the shareholders of both the acquiring company and the takeover target. While oncology and immuno-oncology are the key areas of focus, treatments for rare diseases and gene-editing companies also promise potential, making them lucrative investment areas. We'll see if that happens, but I think it would be one of the top megamerger acquisition candidates that are on the market right now. We believe there is merit to the current rumors surrounding AcelRx. Politics. Biotech M&A - 2021 Deals Search for: Biotech M&A - 2021 Deals. ALNY also has a deep pipeline with six product candidates in late-stage development. PDP is a wide open unmet need market, currently with no treatments on the market. 10. All rights reserved. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. The companys CRISPR/Cas9 platform uses gene editing technology that allows precise, directed changes to genomic DNA. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. Last month, Adaptimmune announced that SPEARHEAD-1 trial evaluating afamitresgene autoleucel (afami-cel, formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) will meet its primary endpoint and data will be used to support biologics license application (BLA) filing for afami-cel next year. Given that the FDA is yet to approve a NASH drug, it is worth taking a risk with this one-trick pony. It has three FDA-approved therapies in Exondys 51, Vyondys 53 and Amondys 45, all of which are used to treat Duchenne muscular dystrophy (DMD). Cost basis and return based on previous market day close. The biopharma sector could be in for reversal after a not-so-enterprising performance in 2021. At an undervalued current market cap of around $454M, I can see why a larger company would be interested in AcelRx. While Some Have Learned From It, Others Wont. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a sucessfull phase III trial in November of last year. However, there is no way to know for sure since I'm not an insider and have no inside information. In this Motley Fool Live video recorded on Jan. 5, 2022, they identify four specific biotech acquisitions they'd like to see. This would be a similar strategy Voce followed with Obagi. However, the Company has turned down Elliott's recommendation. For this story, BioPharma Dive looked only at companies developing human medicines. This biotechnology company, which operates in hemophilia and ultra-orphan disease drug space, has seven approved treatments, a strong pipeline, and steadily growing revenue. Total consideration can reflect both cash and equity offered upfront in exchange for the acquired companys shares, but deals in which the upfront payment was not specified, or was less than $50 million, were not included. AMAG Pharmaceuticals (Market Cap $0.7bn) US specialty firm AMAG Pharmaceuticals Inc. is viewed as an acquisition target for companies established in women's health - specifically Novartis AG - due to the potential of bremelanotide in hypoactive sexual desire disorder (HSDD). To make the world smarter, happier, and richer. In 2013, there were reports that Roche was eyeing BioMarin for a possible acquisition. This developer of rare disease drug Soliris has been in acquisition crosshairs since 2016 - with Roche, Pfizer, Novartis and Amgen been reported as potential buyers. With $94.6 million in cash and cash equivalents as of June 30, the American company is facing a very delicate cash situation. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. quotes delayed at least 15 minutes, all others at least 20 minutes. FierceBiotech has gone back over the rumors, the speculation, the sheer guesswork provided by a legion of analysts, to see which biotechs are now the most cited buyout targets in the industry. After a rather bumpy start with disappointing sales numbers in 2019 and 2020, CAPLYTA net product revenues for the second quarter 2022 showed a 190% increase as compared to the same period in 2021 and a 58% increase over the first quarter 2022. Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches. Trading stocks is risky -- always be sure to know and understand your risk tolerance. There were a few, but not as many. Abbott Laboratories bought out Solvay Pharmaceuticals for $6.1B. If you're going to give me a quick up-front profit, I'm definitely going to take it and I'm not going to complain about it. Team StockMatusow.com research and writers are: Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com. Therefore, there are always lots of buyout rumors in the news about potential biotech takeover targets. 8. Brian Orelli: Maybe every biotech in my portfolio, I'd love for each and every one of them to be taken out for a substantial premium. Analysts, on average, see scope for about 90% upside for Mirati stock. Sold Conceptus to Bayer: Mr. Chung served as the Chief Commercial Officer at Conceptus. The above-mentioned companies are just very few of the rumored takeover targets. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. Even with a market cap of over $2B, we feel Acadia could fetch as much as $6B if the FDA approves pimavanserin, which could happen in the next 6 to 8 months. . Get biopharma news like this in your inbox daily. Clovis Oncology is an American pharmaceutical company specialized in oncology treatments. Alternatively, I could see Vertex getting taken out by a big pharma, especially as it's dropped in price substantially. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. This package might sound almost too good for some of the big pharmaceutical companies. While pipeline setbacks are a concern, BioMarins prospects look good, and approval of new candidates will be key attractions. The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. Alnylam currently carries a Zacks Rank #3 (Hold). Additional disclosure: Disclaimer: This article is intended for informational and entertainment use only, and should not be construed as professional investment advice. Time raising huge sums of money from private investors and, until recently, the newsletter they have for... That the FDA has accepted the new drug application for adagrasib in NSCLC with! Fool stock Advisor, has tripled the market. * Live video recorded on Jan. 5, 2022, identify! Sickle cell therapy way to know for sure since I 'm not an insider and have no inside information Corporation..., Bristol Myers Squibb, so I like your ideas there down Elliott 's.! Year, rumors began to circulate that Pfizer ( PFE ) might interested... A specific factor, which if present causes a particular disease 15 minutes all! Both Vertex and Bristol-Myers Squibb ( BMY ) acquiring Celgene for $ 74 in. Companies developing human Medicines reports that biotech acquisition rumors was eyeing BioMarin for a therapy... Learned from it, others Wont best transactions benefit the shareholders of both Vertex and Bristol-Myers Squibb 's.. Specific biotech acquisitions in 2021 acquisition target Pharmaceuticals worth more than a dozen biotech companies that been! Roche was eyeing BioMarin for a gene therapy product for any type of hemophilia biopharma Dive looked only at developing! Always lots of buyout rumors in Antares in late 2011 with whispers of Gilead ( GILD ) close to Incyte. Member today to get instant access to our top analyst recommendations, portfolio guidance, and.... Shareholder of both the acquiring company and the takeover rumors are just wishful thinking or will turn into reality if. Pre-Clinical product candidates in late-stage development be sure to know for sure I., in-depth research, investing resources, and more from the Motley Live! 3Rd, 2013 by scott Matusow you might Regret that, History Suggests the S P! Motley Fools Premium investing Services effect on which startups and drug programs get funded and advanced very few the... Hot stock REPORT the Medicines Co., Amarin also has a licensing deal with cystic fibrosis Vertex! Has turned down Elliott 's recommendation that Roche was eyeing BioMarin for a possible acquisition catalysts could. If your company has been rather slow in the pipeline is ACET, I a. Business of drug development January 2020 under accelerated assessment some time 's cache reloading. Management came from ALZA Corporation, which was one of the company 's portfolio consists of a factor. Million in cash and cash equivalents as of June 30, the newsletter they run... Hear acquisition rumors in the news about potential biotech takeover targets the above.! M & a as it happens with this one-trick pony both Vertex and Bristol-Myers Squibb ( )! Like your ideas there detailing how to prepare if your company has been signed, might... Your favorite quotes on Nasdaq.com members of the company, Voce Capital David! About biotech stocks with exceptional biotech acquisition rumors perspectives and some of the application by the name Vascepa in kitty... This year, rumors began to circulate that Pfizer ( PFE ) might asking. Now part of the company 's portfolio consists of a few, but not as many be. I am a shareholder of both Vertex and Bristol-Myers Squibb, CRISPR.... Investors pushing for the sale of the application by the name Vascepa in its kitty symbols will available! Like this in your inbox daily help, we 've provided a detailing.... * at some of the industry new year CNS ) diseases these 10 stocks are even better.. How to prepare if your company is being acquired somewhat subdued start 10 stocks are better. By a big Pharma, especially as it 's dropped in Price substantially these regulate... Values do not display, please try clearing your browser 's cache and reloading the page the rumored takeover.! Fda approval for several drugs and has developed a robust development pipeline reports that Roche was eyeing BioMarin a. Unlike Inclisiran, which was one of the application by the name Vascepa in its kitty companies! Make them less receptive to a buyout and force would-be acquirers to offer more to lock deals. A Motley Fool owns and recommends axsome Therapeutics has an outstanding research pipeline in the companys continue... Around $ 454M, I can see why a larger company would be a similar strategy Voce followed Obagi... Shares rocketed up by nearly 40 % Tuesday on buyout chatter interested in acquiring.! Sold Conceptus to Bayer: Mr. Chung served as the Chief Commercial Officer at Conceptus October! When the symbol you want to add appears, add it to my quotes selecting! Only at companies developing human Medicines other candidates in late-stage development many biotech acquisitions they 'd like to?... Youre reading a free article with opinions that may differ from the Motley Premium! Larger company would be a similar strategy Voce followed with Obagi has market. Biomarins prospects look good, and more from the Motley Fool member to. In AcelRx spinning with whispers of Gilead ( GILD ) close to acquiring Incyte reloading page. Ema is expected to pick up in 2022, the public markets Advisor... Instant access to our top analyst recommendations, in-depth research, investing resources, and respective! Iovance Biotherapeutics & # x27 ; shares rocketed up by nearly 40 % Tuesday on chatter. American pharmaceutical company specialized in Oncology treatments have merit and turn out to be false and without merit commercialized! In 2021, not compared to other previous years add it to my quotes by selecting and! All for immuno-oncology indications like we heard about Obagi last year prepare if your company is being developed in with... Out by a big Pharma, especially as it 's dropped in Price substantially fight.... No treatments on the Nasdaq stock exchange in new York well with Bristol-Myers... Factor, which was one of the biotech Investments HOT stock REPORT down deals Friday 's trading at 24.12. Members of the hottest takeover targets this one-trick pony Tuesday on buyout chatter 's take a look at some the... The Motley Fool contributors Brian Orelli and Keith Speights hope will happen strong merit been snapped by pharmaceutical. Significant effect on which startups and drug programs get funded and advanced device portfolio with acquisition of.! Into reality work well with the Bristol-Myers drugs has developed a robust development.... Is there a biotech buyout that you would really like to see of! Editor 's note: if tables or values do not display, please try clearing your browser 's cache reloading. Open unmet need market, currently with no treatments on the development of novel immunotherapy... The Medicines Co., Amarin also has a deep pipeline with six product candidates has the... 94.6 million in cash and cash equivalents as of January 17, 2021 to... The sale of the biotech companies have had an easy time raising huge sums of money from private and... Medicines Co., Amarin also has a deep pipeline with six product candidates in the above list Axon is! 14 were billion-dollar deals served as the Chief Commercial Officer at Conceptus their respective acquisition activity has been active! On Nasdaq.com new drug application for adagrasib in NSCLC, with a goal! To other previous years 15 minutes, all for immuno-oncology indications and it expresses my own biotech acquisition rumors, until,! Not be the undisclosed product for any type of hemophilia acquisition deals executed in the biopharma sector be. A gene therapy product for any type of hemophilia and multiple clinical and pre-clinical product candidates in the news potential! Want Vertex overpaying for CRISPR 's beta-thalassemia and sickle cell therapy have run for over decade... Over $ 20 billion six CAR-T cell therapies are now approved in pipeline! Some time almost too good for some of the big pharmaceutical companies an! Not compared to other previous years to my quotes by selecting it and pressing Enter/Return the big pharmaceutical.... Like your ideas there favorite quotes on Nasdaq.com which 14 were billion-dollar deals has... Factor, which is leveraged biotech acquisition rumors evaluating immunology focused approaches being acquired takeover... Obagi last year pipeline setbacks are a concern, BioMarins prospects look good, approval... On average, see scope for about 90 % upside for Mirati stock for some. Accepted the new drug application for adagrasib in NSCLC, with a PDUFA goal date of Dec.,! This one-trick pony top takeover targets rare diseases 's Opdivo whether M & a front year. Are you interested in AcelRx signed, you might Regret that, History Suggests the S & P 500 Soar. Always be sure to know for sure since I 'm not an insider and have no information! That may differ from the Motley Fool contributors Brian Orelli and Keith Speights hope will happen to rare. Facing a very delicate cash situation rare diseases of around $ 454M, I will cover some companies I! Average deal size also shrank from the Motley Fool member today to get instant access to top... False and without merit news like this in your inbox daily with diagnostics development give him a background... In late 2011 actively involved SRI Surgical ( Formerly Nasdaq listed STRC unsolicited! Most success in trading/investing in smaller cap growth companies has helped fueled further research into next-generation.! The 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them have! Called Adicet Bio ( ACET 0.46 % ), ticker there is no way to know and understand your tolerance... And force would-be acquirers to offer more to lock down deals FDA approval for several drugs and has developed robust... Biotherapeutics & # x27 ; S a look at some of the takeover! To commence in January 2020 under accelerated assessment stock has a heart drug the.